BUZZ-Puma Biotechnology: Shares on the prowl:BUZZ-Puma Biotechnology: Shares on the prowl <\/p>\n
** Puma Biotechnology shares soar 50.3 pct to $56.80 in heavy Monday morning trading; shares rise as high as $69.35, halted multiple times for volatility <\/p>\n
** U.S. Food and Drug Administration posts documents reviewing Puma's neratinib for treating breast cancer ahead of FDA advisory committee meeting on the product on Weds <\/p>\n
** Based on sensitivity analyses conducted, results appear to be generally similar to the primary analysis results, supporting an effect of neratinib, FDA staffers say in review documents <\/p>\n
** Options market has been pricing in a move about 63 pct, positive or negative, in PBYI shares in reaction to neratinib review, JPMorgan analyst Cory Kasimov said in research note last week <\/p>\n
** Short interest in PBYI shares stood at 21.5 pct of shares outstanding as of Apr 27, according to Thomson Reuters data <\/p>\n
** Five analysts rate PBYI shares a \"buy\" or \"strong buy\", two rate \"hold\", according to TR data; median price target is $80 <\/p>\n
** PBYI shares have nearly doubled in 2017, against 9.7 pct rise for Nasdaq Biotechnology index <\/p>\n
(This story has not been edited by timesofindia.com and is autogenerated from a syndicated feed we subscribe to.) <\/p>\n
RELATED <\/p>\n
StyleBistro <\/p>\n
Minivans - Sponsored Ads <\/p>\n
Puppytoob <\/p>\n
<\/p>\n
View original post here: BUZZ-Puma Biotechnology: Shares on the prowl:BUZZ-Puma Biotechnology: Shares on the prowl ** Puma Biotechnology shares soar 50.3 pct to $56.80 in heavy Monday morning trading; shares rise as high as $69.35, halted multiple times for volatility ** U.S. Food and Drug Administration posts documents reviewing Puma's neratinib for treating breast cancer ahead of FDA advisory committee meeting on the product on Weds ** Based on sensitivity analyses conducted, results appear to be generally similar to the primary analysis results, supporting an effect of neratinib, FDA staffers say in review documents ** Options market has been pricing in a move about 63 pct, positive or negative, in PBYI shares in reaction to neratinib review, JPMorgan analyst Cory Kasimov said in research note last week ** Short interest in PBYI shares stood at 21.5 pct of shares outstanding as of Apr 27, according to Thomson Reuters data ** Five analysts rate PBYI shares a \"buy\" or \"strong buy\", two rate \"hold\", according to TR data; median price target is $80 ** PBYI shares have nearly doubled in 2017, against 9.7 pct rise for Nasdaq Biotechnology index (This story has not been edited by timesofindia.com and is autogenerated from a syndicated feed we subscribe to.) RELATED StyleBistro Minivans - Sponsored Ads Puppytoob Continue reading
\nPuma Biotechnology: Shares on the prowl - Times of India<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"